Last Updated:December 10, 2025, 11:28 IST

“Amazon to date has invested USD 40 billion in India since 2010. Now we will invest another USD 35 billion by 2030 across all our businesses in India,” Agarwal said.

E-commerce giant Amazon is set to invest a mega-investment of USD 35 billion, over Rs 3.14 lakh crore, in India by 2030 across its businesses with a focus on AI-driven digitisation, export growth and job creation, a senior company official said on Wednesday.

Senior VP Emerging Markets, Amit Agarwal, made the announcement during the Amazon Smbhav Summit, saying the company has set a target to quadruple exports from India to USD 80 billion from about USD 20 billion.

“Amazon to date has invested USD 40 billion in India since 2010. Now we will invest another USD 35 billion by 2030 across all our businesses in India,” Agarwal said.

Amazon’s investment plan is two times of Microsoft’s investment plan of USD 17.5 billion and close to 2.3 times that of Google’s USD 15 billion investment plan by 2030.

With this investment, Amazon will become the largest foreign investor in India, according to a Keystone report compiled from publicly available data.

In May 2023, Amazon announced plans to invest USD 12.7 billion in India by 2030 into its local cloud and AI infrastructure across Telangana and Maharashtra. The company has already invested USD 3.7 billion in India between 2016 and 2022.

The company has invested at scale towards building physical and digital infrastructure, including fulfilment centres, transportation networks, data centres, digital payments infrastructure and technology development.

According to the Keystone report, Amazon has digitized over 12 million small businesses and enabled USD 20 billion in cumulative ecommerce exports, while supporting approximately 2.8 million direct, indirect, induced and seasonal jobs across industries in India in 2024.

(With inputs from agencies)

Click here to add News18 as your preferred news source on Google.

Follow News18 on Google. Join the fun, play games on News18. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.

Read More

Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark indices, opened in green on Wednesday. While Nifty50 was above 25,850, BSE Sensex was up over 100 points. At 9:17 AM, Nifty50 was trading at 25,865.25, up 26 points or 0.099%. BSE Sensex was at 84,804.28, up 138 points.Dr. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited says, “As the year slowly draws to a close the market structure is becoming challenging. Heavy selling in the broader market is justified since valuations have been elevated and kept high only on the strength of liquidity. This is unsustainable. But the weakness in the overall market and sustained selling by FIIs are a bit disappointing. A major concern is the excessive delay in the finalisation of the US-India trade deal. A remark by President Trump yesterday that action should be taken on India for dumping rice in the US hurt sentiments further.”“Fundamentals are turning in favour of India. Higher growth and corporate earnings are achievable in the quarters ahead. The fiscal and monetary stimulus provided this year have started producing results. The excessively low inflation rate, which impacted nominal GDP growth, also will start rising in the coming quarters. This is significant since corporate earnings growth will be influenced more by nominal GDP growth rather than by real GDP growth. The fact that valuations in the large cap segment have become fair is another positive. These positive factors will start weighing on the market soon. Investors have to keep faith and wait patiently for the fundamentals to play out.”The S&P 500 declined on Tuesday as investors anticipated hawkish Federal Reserve messaging despite potential rate cuts. JPMorgan contributed significantly to the benchmark index’s decline following the bank’s announcement of substantial 2026 expenses.Asian markets showed modest gains following Wall Street’s subdued session, with investors awaiting the Federal Reserve’s final interest rate decision of the year.Foreign portfolio investors recorded net sales of Rs 3,760 crore on Tuesday, whilst domestic institutional investors showed net purchases of Rs 6,225 crore.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)

Ads for prostate supplements and home testing kits have been banned over concerns they could mislead vulnerable people or steer them away from appropriate medical advice.

The Advertising Standards Authority (ASA) banned ads for four supplement brands – Nutrisslim, Nutreance, Muxue Trade and Impact Herbs – for making claims that their products could treat medical issues such as enlarged prostate, urinary flow problems or prostate inflammation.

None of the products were authorised medicines and advertising rules state that food products, including supplements, cannot make medicinal claims.

Nutreance, trading as Top 5 Supplements, said its ads did not state or imply that its product treated, cured or prevented any disease or medical symptoms, and the ads made no references to diseases, diagnoses, pathological conditions or clinical outcomes.

Nutrisslim, trading as Nature’s Finest by Nutrisslim, said the claims used in its ads related to botanical ingredients, which it understood could be used in advertising.

It said “visual materials” featuring a doctor and any related references had been removed from its website, including a reference to the product being “doctor-formulated”.

Impact Herbs, trading as Impact Supps, and Muxue did not respond to the ASA.

The ASA also banned ads from two home testing kit companies – Self Check and Lifelab Testing – for claiming that Prostate-Specific Antigen (PSA) tests could diagnose or rule out prostate cancer.

Self Check said its products were CE certified for self testing in line with UK legislation.

It further said that every product page contained a disclaimer that informed consumers that because the tests were not 100% at diagnosing a specific medical condition, they may wish to speak to their NHS GP first, who could arrange a test if needed.

It also said that it had removed the word “cancer” in the headings and descriptions of the Google ads for the product.

Lifelab also said it held the correct CE markings for an in-vitro diagnostic device, and that the product was suitable for sale in the UK.

It also said the ads had been removed and would not be used again.

A PSA test alone cannot do either, and in both cases the ads failed to make clear that these tests had limitations.

The ASA came across the ads during a sweep of healthcare claims using its AI-powered Active Ad Monitoring system.

The ASA said many of the claims it had seen in the latest investigations were “unacceptable”, and had not only broken a number of its rules but risked misleading vulnerable people, or steering those who needed it away from appropriate medical advice.

It said this was “especially worrying when it comes to men’s health”, adding that prostate symptoms could be worrying and, for some, difficult to talk about, meaning that ads promising quick fixes or simple answers “can seem even more appealing”.

However, misleading claims could give false reassurance or make it harder for people to know when to speak to a doctor, “which is why it’s so important that information about prostate health is accurate and responsible”, the ASA said.

Jess Tye, regulatory projects manager at the ASA, said: “When it comes to health, people deserve honesty.

“Misleading ads about prostate supplements or tests can cause real harm, and today’s rulings hold advertisers to account.

“We’re continuing to monitor this sector closely, using our AI tools to spot problem ads early on. And if someone does have a concern about an ad they’ve seen, we’d encourage them to get in touch.”

Joseph Burt, head of diagnostics and general medical devices at the Medicines and Healthcare products Regulatory Agency (MHRA), said: “The MHRA welcomes the ASA’s action to tackle misleading claims about PSA home-testing kits.

“At-home or over-the-counter PSA tests help members of the public monitor their prostate health, but are not a definitive test for prostate cancer. These tests must not claim to detect prostate cancer, and consumers should carefully check the labelling and read the instructions for use.

“The MHRA has recognised the expansion of over-the-counter tests, including PSA tests.

“As part of our surveillance of medical devices, we continue to monitor the safety of these devices. Manufacturers of these tests have an important role in ensuring information about direct-to-consumer tests are put into context for the general public who use these tests as well as monitoring the use of the tests.”

Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: “We are very pleased to see the ASA getting proactive in identifying and banning these dangerous and misleading adverts.

“There is no evidence that supplements can treat, cure or prevent prostate problems, and they should not be used in place of speaking to a doctor about your risk of prostate cancer, or more general concerns about your prostate health.

“While there are a range of at-home PSA self-test kits on the market currently, the accuracy and safety of these tests is not proven, and so we only recommend getting a PSA blood test from a healthcare professional.

“It’s important to remember that prostate cancer often has no symptoms in its earlier, more treatable stages, so it’s crucial for a man to understand his own risk and not to wait for potential signs or symptoms. Any men worried about their risk of prostate cancer or looking to find out more about testing can take Prostate Cancer UK’s 30-second online Risk Checker.”

Consumers can check the registration status of PSA tests via the MHRA’s Public Access Registrations Database.

Anyone concerned about the quality or safety of a PSA test should report it to the MHRA via the Yellow Card scheme.